Back to blog Celebrity

Jon Moeller and Karen Lynch: Two 2021 CEOs, Two Very Different Endings

Emma

November 13, 2026

No comments

In 2021, two executives stepped into the top job at two of America’s best-known household names. Jon Moeller took over Procter & Gamble (P&G). Karen Lynch took over CVS Health. Five years on, neither of them holds that job any more, and the way each one left says a lot about how corporate leadership actually works.

This guide sets out who they are, how they got there, why they stepped aside, and what the companies look like today under their successors. Every figure below is linked to its source at the end of the article..

Quick comparison

	Jon Moeller	Karen Lynch
Company	Procter & Gamble	CVS Health
Became CEO	1 November 2021	1 February 2021
Left the CEO role	31 December 2025 (planned)	17 October 2024 (sudden)
Successor	Shailesh Jejurikar	David Joyner
Born	11 June 1964, Chicago	30 December 1963
Education	Cornell: BS biology (1986), MBA (1988)	Boston College (accounting, CPA); MBA, Boston University
Career path	One employer for 38 years	Cigna, Magellan Health, Aetna, then CVS
Where they are now	Retired from P&G in August 2026	Boards, advisory work, speaking, a leadership institute

Jon Moeller: the lifer

Moeller joined P&G on 1 September 1988, straight after finishing his MBA at Cornell, and started as a cost analyst. He built the rest of his career inside a single company, moving through about fifteen jobs before becoming chief financial officer in 2009, a post he held for more than twelve years. His path into P&G was partly personal: his future wife, Lisa Sauer, a Cornell classmate, had interned at the company and encouraged him to look at it.

Before the top job he also served as chief operating officer. P&G announced him as CEO in July 2021, with the change taking effect on 1 November that year, and he carried the chairman, president and CEO titles until the end of 2025.

P&G’s own biography credits his years in the senior team with adding more than $17 billion in sales, over $6 billion in profit and close to $180 billion in market value. That is the company’s self-assessment, so treat it as the official version rather than an independent audit.

How his tenure looked in the numbers

P&G’s annual report shows net sales rising from about $80.2 billion in fiscal 2022 to $87.0 billion in fiscal 2026. The final year, which ended 30 June 2026, was modest: organic sales grew 1%, gross margin slipped 1 percentage point to 50.2%, and core earnings per share came in at $6.89. Beauty was the standout, with segment sales up 7% to $16.0 billion.

The takeaway is that P&G is a steady, mature business. Growth is measured in single digits, and the story is about pricing discipline, productivity savings and marketing spend rather than dramatic reinvention.

The handover

In July 2025 P&G announced that its chief operating officer, Shailesh Jejurikar, would take over as CEO on 1 January 2026, with Moeller becoming executive chairman. The transition was then completed in 2026: Jejurikar became board chairman on 1 August, Moeller left the board on 31 July and retired from the company on 14 August, after 38 years.

That is textbook succession planning: a long runway, an insider successor (Jejurikar joined P&G in 1989) and a clear end date.

Karen Lynch: the career-switcher

Lynch’s route was almost the opposite. She trained as an accountant, qualified as a CPA, and began at Ernst & Young in Boston, specialising in insurance. From there she moved to Cigna, where she rose to lead group insurance and dental businesses, then became president of Magellan Health in 2009. In 2012 she joined Aetna, and in 2015 she became its first female president.

She arrived at CVS in November 2018 when CVS acquired Aetna for roughly $69 billion. On 1 February 2021 she became CEO, succeeding long-time chief Larry Merlo. At that point CVS was the largest company ever to be led by a woman, and she was the highest-ranking female chief executive on the Fortune 500 list.

What she did as CEO

Her early years were dominated by the pandemic, with CVS administering COVID-19 vaccines across all fifty states and in tens of thousands of long-term care facilities. After that she pushed the company from a drugstore-and-insurance business towards delivering care itself, including large purchases of Signify Health (about $8 billion) and Oak Street Health (about $10.6 billion).

Why she left

The strategy collided with rising medical costs, particularly in Medicare Advantage, the privately run version of Medicare. CVS cut its financial outlook three times in 2024, the share price had fallen roughly a fifth, and an activist investor was pressing the board. On 17 October 2024 CVS announced that David Joyner, who had run its pharmacy benefit business, would replace her, alongside a warning that third-quarter earnings would miss forecasts.

She did not walk away empty-handed or without a bridge: a regulatory filing showed a six-month advisory arrangement at $375,000 per month and an extended non-compete. Her 2023 pay package was about $21.6 million, a ratio of 392 to 1 against the median CVS worker.

After CVS

Lynch published a memoir, Taking Up Space, in March 2024, before leaving. Since stepping down she has taken board seats, advised companies on CEO succession, spoken publicly and set up a leadership institute. In a Fortune interview she described the sudden quiet after a CEO schedule as hard at first.

Also Read This : Misha Ezratti Net Worth 2026: Career Family and GL Homes

What the companies look like now

CVS Health under Joyner. Joyner became Chair as well as CEO on 1 January 2026. Third-quarter 2026 revenue reached $108.4 billion, up 5.4% from a year earlier, with adjusted earnings per share of $2.09. The company raised its full-year outlook to at least $420 billion in revenue and at least $8.20 in adjusted EPS. For context, the same quarter a year earlier produced a GAAP loss, so this is a genuine turnaround rather than steady growth. CVS reported roughly 9,000 retail pharmacy locations as of September 2025.

P&G under Jejurikar. Q4 fiscal 2026 net sales were $21.2 billion, up 2%, with organic sales flat. Nine of ten product categories and all seven regions held or grew organic sales across the year, but P&G also acknowledged a more challenging economic backdrop.

Different leadership styles, honestly compared

It is tempting to wrap two high-profile executives in flattering adjectives. The record supports a more specific comparison.

Depth versus range. Moeller’s authority came from knowing one company intimately. Lynch’s came from seeing several parts of healthcare, which suited a strategy built on joining insurance, pharmacy and clinics.
Incremental versus ambitious. P&G under Moeller stayed close to its playbook. CVS under Lynch made large, expensive bets on care delivery.
Risk profile. The incremental approach produced slow but stable results. The ambitious one produced headline-making deals and, eventually, margin pressure that the market punished.

Neither style is automatically better. They fit different industries: consumer goods reward consistency, while US healthcare punishes misjudging cost trends.

Are Jon Moeller and Karen Lynch connected?

No public evidence links them personally, professionally or through family. They led unrelated, separately listed companies. Pairing them is a feature of search behaviour and of the shared 2021 start date, not of any shared history.

What about their net worth?

Reliable, audited figures for the personal wealth of retired executives are hard to find, and the estimates that circulate online rarely cite a method. Rather than repeat unsourced numbers, this article sticks to disclosed pay, such as Lynch’s 2023 compensation. For P&G executives, the company’s annual proxy statement is the primary source, and it is worth checking each year.

Frequently asked questions

Who are Jon Moeller and Karen Lynch?

Jon Moeller is the former chairman, president and CEO of Procter & Gamble, who retired from the company in August 2026. Karen Lynch is the former CEO of CVS Health, who held the role from February 2021 to October 2024.

Is Jon Moeller still the CEO of P&G?

No. Shailesh Jejurikar became CEO on 1 January 2026 and added the chairman role on 1 August 2026.

Is Karen Lynch still the CEO of CVS Health?

No. David Joyner replaced her in October 2024 and has also been Chair since 1 January 2026.

Why did Karen Lynch leave CVS?

CVS had cut its earnings outlook three times in 2024 amid higher medical costs, and the board decided on a change as another shortfall was announced.

Where did Jon Moeller study?

Cornell University, where he earned a biology degree in 1986 and an MBA in 1988.

Where did Karen Lynch study?

Boston College, for her undergraduate degree in accounting, and Boston University for her MBA.

Did the two ever work together?

There is no evidence that they did.

Sources

Written By